Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)


beclometasone / formoterol

This medicine is authorised for use in the European Union.


Riarify is a medicine used in adults to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Riarify is used for maintenance (continuing) treatment in patients whose disease is not adequately controlled despite treatment with a combination of two COPD medicines consisting of a long-acting beta-2 agonist plus either an inhaled corticosteroid or a long-acting muscarinic receptor antagonist. Beta-2 agonists and muscarinic receptor antagonists help to widen the airways; corticosteroids reduce inflammation in the airways and lungs.

This medicine is the same as Trimbow, which is already authorised in the EU. The company that makes Trimbow has agreed that its scientific data can be used for Riarify (‘informed consent’).

Riarify contains the active substances beclometasone, formoterol and glycopyrronium bromide.

This EPAR was last updated on 30/06/2023

Authorisation details

Product details
Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)
Agency product number
Active substance
  • formoterol fumarate dihydrate
  • glycopyrronium
  • Beclometasone dipropionate
International non-proprietary name (INN) or common name
  • beclometasone
  • formoterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Chiesi Farmaceutici S.p.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Via Palermo 26/A
43122 Parma

Product information

09/12/2022 Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.) - EMEA/H/C/004836 - R/0022

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs for obstructive airway diseases

Therapeutic indication

Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptoms control and prevention of exacerbations see section 5.1).

Assessment history

How useful was this page?

Add your rating
1 rating
1 rating
1 rating